Abstract
The ruthenium compound KP1019 has demonstrated promising anticancer activity in a pilot clinical trial. This study aims to evaluate the intracellular uptake/binding patterns of KP1019 and its sodium salt KP1339, which is currently in a phase I–IIa study. Although KP1339 tended to be moderately less cytotoxic than KP1019, IC50 values in several cancer cell models revealed significant correlation of the cytotoxicity profiles, suggesting similar targets for the two drugs. Accordingly, both drugs activated apoptosis, indicated by caspase activation via comparable pathways. Drug uptake determined by inductively coupled plasma mass spectrometry (ICP-MS) was completed after 1 h, corresponding to full cytotoxicity as early as after 3 h of drug exposure. Surprisingly, the total cellular drug uptake did not correlate with cytotoxicity. However, distinct differences in intracellular distribution patterns suggested that the major targets for the two ruthenium drugs are cytosolic rather than nuclear. Consequently, drug–protein binding in cytosolic fractions of drug-treated cells was analyzed by native size-exclusion chromatography (SEC) coupled online with ICP-MS. Ruthenium–protein binding of KP1019- and KP1339-treated cells distinctly differed from the platinum binding pattern observed after cisplatin treatment. An adapted SEC-SEC-ICP-MS system identified large protein complexes/aggregates above 700 kDa as initial major binding partners in the cytosol, followed by ruthenium redistribution to the soluble protein weight fraction below 40 kDa. Taken together, our data indicate that KP1019 and KP1339 rapidly enter tumor cells, followed by binding to larger protein complexes/organelles. The different protein binding patterns as compared with those for cisplatin suggest specific protein targets and consequently a unique mode of action for the ruthenium drugs investigated.
Similar content being viewed by others
Abbreviations
- GSH:
-
Glutathione
- HMW/LMW:
-
Ruthenium-content ratio between the high molecular weight fraction and the low molecular weight fraction
- ICP-MS:
-
Inductively coupled plasma mass spectrometry
- JC-1:
-
5,5′,6,6′-Tetrachloro-1,1′,3,3′-tetraethylbenzimidazolylcarbocyanine iodide
- KP1019:
-
Indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)]
- KP1339:
-
Sodium trans-[tetrachlorobis(1H-indazole)ruthenate(III)]
- PARP:
-
Poly(ADP-ribosyl)polymerase
- PBS:
-
Phosphate-buffered saline
- SEC:
-
Size-exclusion chromatography
- Tris:
-
Tris(hydroxymethyl)aminomethane
References
Bruijnincx PC, Sadler PJ (2008) Curr Opin Chem Biol 12:197–206
Heffeter P, Jungwirth U, Jakupec M, Hartinger C, Galanski M, Elbling L, Micksche M, Keppler B, Berger W (2008) Drug Resist Updat 11:1–16
Cossa G, Gatti L, Zunino F, Perego P (2009) Curr Med Chem 16:2355–2365
Hartinger CG, Zorbas-Seifried S, Jakupec MA, Kynast B, Zorbas H, Keppler BK (2006) J Inorg Biochem 100:891–904
Kapitza S, Jakupec MA, Uhl M, Keppler BK, Marian B (2005) Cancer Lett 226:115–121
Kapitza S, Pongratz M, Jakupec MA, Heffeter P, Berger W, Lackinger L, Keppler BK, Marian B (2004) J Cancer Res Clin Oncol 226:115–121
Cetinbas N, Webb MI, Dubland JA, Walsby CJ (2010) J Biol Inorg Chem 15:131–145
Sulyok M, Hann S, Hartinger CG, Keppler BK, Stingeder G, Koellensperger G (2005) J Anal At Spectrom 20:856–863
MacKenzie EL, Iwasaki K, Tsuji Y (2008) Antioxid Redox Signal 10:997–1030
Heffeter P, Pongratz M, Steiner E, Chiba P, Jakupec MA, Elbling L, Marian B, Korner W, Sevelda F, Micksche M, Keppler BK, Berger W (2005) J Pharmacol Exp Ther 312:281–289
Lipponer KG, Vogel E, Keppler BK (1996) Met Based Drugs 3:243–260
Peti W, Pieper T, Sommer, Keppler BK, Giester G (1999) Eur J Inorg Chem 1551–1555
Heffeter P, Jakupec MA, Korner W, Wild S, von Keyserlingk NG, Elbling L, Zorbas H, Korynevska A, Knasmuller S, Sutterluty H, Micksche M, Keppler BK, Berger W (2006) Biochem Pharmacol 71:426–440
Sagmeister S, Eisenbauer M, Pirker C, Mohr T, Holzmann K, Zwickl H, Bichler C, Kandioler D, Wrba F, Mikulits W, Gerner C, Shehata M, Majdic O, Streubel B, Berger W, Micksche M, Zatloukal K, Schulte-Hermann R, Grasl-Kraupp B (2008) Br J Cancer 99:151–159
Janson V, Andersson B, Behnam-Motlagh P, Engstrom KG, Henriksson R, Grankvist K (2008) Cell Physiol Biochem 22:45–56
Bunz F, Fauth C, Speicher MR, Dutriaux A, Sedivy JM, Kinzler KW, Vogelstein B, Lengauer C (2002) Cancer Res 62:1129–1133
Egger A, Rappel C, Jakupec MA, Hartinger CG, Heffeter P, Keppler BK (2009) J Anal At Spectrom 24:51–61
Koellensperger G, Daubert S, Erdmann R, Hann S, Rottensteiner HP (2007) Chem Biol 388:1209–1214
Heffeter P, Jakupec MA, Korner W, Chiba P, Pirker C, Dornetshuber R, Elbling L, Sutterluty H, Micksche M, Keppler BK, Berger W (2007) Biochem Pharmacol 73:1873–1886
Berger W, Elbling L, Micksche M (2000) Int J Cancer 88:293–300
Korynevska A, Heffeter P, Matselyukh B, Elbling L, Micksche M, Stoika R, Berger W (2007) Biochem Pharmacol 74:1713–1726
Hall AG (1999) Adv Exp Med Biol 457:199–203
Hann S, Obinger C, Stingeder G, Paumann M, Furtmüller PG, Koellensperger G (2006) J Anal At Spectrom 21:1224–1231
Pizarro AM, Sadler PJ (2009) Biochimie 91:1198–1211
Sakurai H, Okamoto M, Hasegawa M, Satoh T, Oikawa M, Kamiya T, Arakawa K, Nakano T (2008) Cancer Sci 99:901–904
Pawarode A, Shukla S, Minderman H, Fricke SM, Pinder EM, O’Loughlin KL, Ambudkar SV, Baer MR (2007) Cancer Chemother Pharmacol 60:179–188
Brabec V, Novakova O (2006) Drug Resist Updat 9:111–122
Smalley KS, Contractor R, Haass NK, Kulp AN, Atilla-Gokcumen GE, Williams DS, Bregman H, Flaherty KT, Soengas MS, Meggers E, Herlyn M (2007) Cancer Res 67:209–217
Xie P, Williams DS, Atilla-Gokcumen GE, Milk L, Xiao M, Smalley KS, Herlyn M, Meggers E, Marmorstein R (2008) ACS Chem Biol 3:305–316
Bullock AN, Russo S, Amos A, Pagano N, Bregman H, Debreczeni JE, Lee WH, von Delft F, Meggers E, Knapp S (2009) PLoS One 4:e7112
Bergamo A, Sava G (2007) Dalton Trans 1267–1272
Alessio E, Mestroni G, Bergamo A, Sava G (2004) Curr Top Med Chem 4:1525–1535
Schluga P, Hartinger CG, Egger A, Reisner E, Galanski M, Jakupec MA, Keppler BK (2006) Dalton Trans 1796–1802
Bursch W, Karwan A, Mayer M, Dornetshuber J, Frohwein U, Schulte-Hermann R, Fazi B, Di Sano F, Piredda L, Piacentini M, Petrovski G, Fesus L, Gerner C (2008) Toxicology 254:147–157
Jung T, Grune T (2008) IUBMB Life 60:743–752
Meng X, Leyva ML, Jenny M, Gross I, Benosman S, Fricker B, Harlepp S, Hebraud P, Boos A, Wlosik P, Bischoff P, Sirlin C, Pfeffer M, Loeffler JP, Gaiddon C (2009) Cancer Res 69:5458–5466
Acknowledgments
We are indebted to Vera Bachinger and Maria Eisenbauer for the skilful handling of cell cultures, Elisabeth Rabensteiner, Rosa-Maria Weiss, as well as Christian Balcarek for competent technical assistance, and Irene Herbacek for fluorescence-activated cell sorting analysis. Many thanks go to Rita Dornetshuber, Christian Hartinger, Leonilla Elbling, and Michael Jakupec for inspiring discussions. This work was performed within the Research Platform Translational Cancer Therapy Research Vienna and supported by the Austrian Science Fond grants L212 and L473, by Bürgermeister Fond der Stadt Wien grant 2460, as well as by FFG grant 811591.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Heffeter, P., Böck, K., Atil, B. et al. Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339. J Biol Inorg Chem 15, 737–748 (2010). https://doi.org/10.1007/s00775-010-0642-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00775-010-0642-1